An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors

Anti-Cancer Drugs

Volumn 27, Issue 4, 2016, Pages 342-348

  Awada, Ahmad ^a   Campone, Mario ^b   Varga, Andrea ^c,d   Aftimos, Philippe ^a   Frenel, Jean Sébastien ^b   Bahleda, Rastilav ^c,d   Gombos, Andrea ^a   Bourbouloux, Emmanuelle ^b   Soria, Jean Charles ^c,d  

^a JULES BORDET INSTITUTE   (Belgium)

^b UMR INSERM U892 CNRS 6299   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

CEP 8983; Chemotherapy regimen; Poly (ADP ribose) polymerase 1 inhibitor

Indexed keywords

4,5,6,7 TETRAHYDRO 11 METHOXY 1H CYCLOPENTA[A]PYRROLO[3,4 C]CARBAZOLE 1,3(2H) DIONE; CEP 9722; CISPLATIN; GEMCITABINE; ANTINEOPLASTIC AGENT; CARBAZOLE DERIVATIVE; CEP-9722; DEOXYCYTIDINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PARP1 PROTEIN, HUMAN; PARP2 PROTEIN, HUMAN; PHTHALIMIDE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BILE DUCT CARCINOMA; BLADDER CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; COLORECTAL CANCER; DECREASED APPETITE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; LUNG CANCER; MALE; MANTLE CELL LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; STOMACH CANCER; TREATMENT DURATION; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DOSE RESPONSE; LUNG NEOPLASMS; LYMPHOMA, MANTLE-CELL; METABOLISM; MIDDLE AGED; NEOPLASMS; OVARIAN NEOPLASMS; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBAZOLES; CISPLATIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOMA, MANTLE-CELL; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS; OVARIAN NEOPLASMS; PHTHALIMIDES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84954563985     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000336     Document Type: Article

References (13)

1. Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 2000; 6:2860-2867.
2. Masutani M, Nozaki T, Nakamoto K, Nakagama H, Suzuki H, Kusuoka O, et al. The response of Parp knockout mice against DNA damaging agents. Mutat Res 2000; 462:159-166.
3. Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, Zhao H, Wan W, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003; 2:371-382.
4. Jacob DA, Bahra M, Langrehr JM, Boas-Knoop S, Stefaniak R, Davis J, et al. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells. J Gastroenterol Hepatol 2007; 22:738-748.
5. Drew Y, Plummer R. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drug Resist Updat 2009; 12:153-156.
6. Węsierska-Gądek J, Mauritz M, Mitulovic G, Cupo M. Differential potential of pharmacological PARP inhibitors for inhibiting cell proliferation and inducing apoptosis in human breast cancer cells. J Cell Biochem 2015; 116:2824-2839.
7. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015; 33:244-250.
8. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15:852-861.
9. Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, et al. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 2012; 18:2344-2351.
10. Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res 2011; 71:5626-5634.
11. Miknyoczki S, Chang H, Grobelny J, Pritchard S, Worrell C, McGann N, et al. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol Cancer Ther 2007; 6:2290-2302.
12. Plummer R, Stephens P, Aissat-Daudigny L, Cambois A, Moachon G, Brown PD, Campone M. Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors. Cancer Chemother Pharmacol 2014; 74:257-265.
13. Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 2015; 16:87-97.